ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 3

CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

March 1, 2024

Benjamin Garmezy, MD, Martin H. Voss, MD, Chandler Park, MD, MSc, FACP, David A. Braun, MD, PhD, Laurence Albiges, MD, PhD

Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.

EP. 1: First-Line Treatments for Advanced Clear Cell RCC

EP. 2: Long-Term Follow-Up from CheckMate 214 in Advanced RCC

Now Viewing

EP. 3: CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

EP. 4: Recent Subgroup Analyses from the CLEAR study in Advanced RCC

EP. 5: LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

EP. 6: Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC

EP. 7: CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC

EP. 8: Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC

EP. 9: LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research

EP. 10: Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC

EP. 11: CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC

EP. 12: Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC

EP. 13: Clinical Insights on Belzutifan in Advanced RCC

EP. 14: Overview of Non–Clear Cell RCC

EP. 15: TKI Monotherapy Data in Non–Clear Cell RCC

EP. 16: KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

EP. 17: Nivolumab Plus Cabozantinib in Non–Clear Cell RCC

EP. 18: Future Perspectives and Unmet Needs in Renal Cell Carcinoma